An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

Completed · Phase 2

Conditions studied: Mycosis Fungoides

In brief

To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or AP ointment who did not achieve a complete response.

Key facts

Study ID: NCT00535470
Run by: Yaupon Therapeutics
People needed: 100
Starts: 2007-07-01
Expected to finish: 2011-03-01
Last updated by the study team: 2012-08-09

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have completed the treatment phase of the Yaupon Therapeutics-sponsored Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not achieved a complete response.

You may not qualify if…

Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception

Where it is running

Stanford University Medical Center — Stanford, California, United States
Northwestern University-Dept. of Dermatology — Chicago, Illinois, United States
Columbia University, Dept of Dermatology — New York, New York, United States
NYU Medical Center Dept. of Dermatology — New York, New York, United States
Duke University Medical Center — Durham, North Carolina, United States
Oklahoma University — Tulsa, Oklahoma, United States
Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
University of Texas, Southwestern Medical Center — Dallas, Texas, United States
The University of Texas, M.D. Anderson Cancer Center — Houston, Texas, United States
Utah Clinical Trials, LLC — Salt Lake City, Utah, United States
University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.